Dicot's study results presented today at European Society for Sexual Medicine
Uppsala, February 17, 2023. Today the pharmaceutical company Dicot presented the latest study of the mechanism of action of LIB-01 at the European Society for Sexual Medicine's annual congress in Rotterdam. The study shows that the mechanism of action differs from today's most common potency drugs, PDE5 inhibitors, and that LIB-01 may thus represent a completely new generation of potency drugs.The European Society for Sexual Medicine (ESSM) is a leading scientific organization in sexual medicine. The annual congress is now underway, bringing together prominent researchers and doctors in the